Cuba has introduced a cancer treatment known as Vaxira, which researchers say is designed to support the immune system in recognizing and attacking lung cancer cells.

The therapy is described as a form of immunotherapy rather than a preventive vaccine. According to Cuban scientific institutions involved in its development, Vaxira works by training the body’s immune response to identify cancer-related cells and help slow disease progression, particularly in advanced lung cancer cases.

The treatment has been developed within Cuba’s state biotechnology sector, which has long focused on cancer research and immune-based therapies. Officials say the approach is part of broader efforts to expand domestic medical innovation in oncology.

Cuban diplomatic representatives have also highlighted the development in a political context, stating that such scientific progress has been achieved despite decades of US economic restrictions on the country.

However, detailed international trial data, regulatory approvals outside Cuba, and large-scale independent evaluations have not been fully disclosed in the announcement. As with other cancer immunotherapies, broader global validation would typically require extensive clinical review.

Cuba has previously developed and used similar therapeutic cancer treatments domestically, and Vaxira is being presented as part of that continuing research pipeline rather than a standalone global breakthrough.